Skip Navigation

European Heart Journal 2008 29(4):425-426; doi:10.1093/eurheartj/ehm628
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Holdaas, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holdaas, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?

Hallvard Holdaas*

Section of Nephrology, Medical Department, The National Hospital, Sognsvannsvn 20, N-0027 Oslo, Norway

* Corresponding author. Tel: +47 2307 1246, Fax: +47 2307 1247. Email : Hallvard.Holdaas@rikshospitalet.no

This editorial refers to ‘The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure’ by P.S. Sever et al.,{dagger} on page 499

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

Cholesterol lowering with statin therapy has been shown to reduce cardiovascular events in a variety of patient categories, ranging from patients with established cardiovascular disease to high-risk individuals with no previous history.1 The degree of benefit relates primarily to a patient's absolute risk of cardiovascular events and to the absolute reduction in low-density lipoprotein (LDL)-cholesterol. The optimal intensity of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure
Peter S. Sever, Neil R. Poulter, Bjorn Dahlof, Hans Wedel, Gareth Beevers, Mark Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin T. O’Brien, Jan Östergren, and on behalf of the ASCOT Investigators
EHJ 2008 29: 499-508. [Abstract] [FREE Full Text]